Drugs / LESOFAVUMAB
LESOFAVUMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02528903 | Aug 2015 → Jan 2016 | — | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LESOFAVUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298041 ↗ |
| Known as | MHAB5553A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02528903 ↗ |
| Known as | RG70026 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298041 ↗ |
| Known as | RO7045557 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298041 ↗ |
| Modality | Monoclonal antibody | “Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A” PMID 28559255 ↗ Jul 2017 |
| Route | Intravenous | “single intravenous (i.v.) dose of 120, 1,200, 3,600, 8,400, or 10,800 mg MHAB5553A” PMID 28559255 ↗ Jul 2017 |